Citadel Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $204M | Sell |
2,911,800
-61,800
| -2% | -$3.2M | 0.02% | 550 |
|
|
2026
Q1 | $151M | Sell |
2,973,600
-1,485,600
| -33% | -$69.3M | 0.02% | 591 |
|
|
2025
Q4 | $132M | Sell |
4,459,200
-1,565,700
| -26% | -$42.5M | 0.02% | 695 |
|
|
2025
Q3 | $156M | Buy |
6,024,900
+1,827,500
| +44% | +$51M | 0.02% | 596 |
|
|
2025
Q2 | $116M | Sell |
4,197,400
-697,900
| -14% | -$18.4M | 0.02% | 680 |
|
|
2025
Q1 | $139M | Buy |
4,895,300
+1,482,200
| +43% | +$52.6M | 0.03% | 517 |
|
|
2024
Q4 | $142M | Buy |
3,413,100
+896,300
| +36% | +$42.8M | 0.02% | 548 |
|
|
2024
Q3 | $168M | Buy |
2,516,800
+702,300
| +39% | +$64.5M | 0.03% | 432 |
|
|
2024
Q2 | $215M | Sell |
1,814,500
-331,700
| -15% | -$42M | 0.04% | 324 |
|
|
2024
Q1 | $229M | Sell |
2,146,200
-192,900
| -8% | -$19.4M | 0.04% | 322 |
|
|
2023
Q4 | $233M | Sell |
2,339,100
-351,200
| -13% | -$29.5M | 0.05% | 296 |
|
|
2023
Q3 | $278M | Buy |
2,690,300
+832,700
| +45% | +$92.9M | 0.06% | 217 |
|
|
2023
Q2 | $226M | Sell |
1,857,600
-47,200
| -2% | -$6.3M | 0.05% | 277 |
|
|
2023
Q1 | $293M | Sell |
1,904,800
-2,392,200
| -56% | -$395M | 0.06% | 203 |
|
|
2022
Q4 | $772M | Buy |
4,297,000
+2,241,900
| +109% | +$367M | 0.18% | 60 |
|
|
2022
Q3 | $243M | Buy |
2,055,100
+237,800
| +13% | +$36.1M | 0.06% | 245 |
|
|
2022
Q2 | $260M | Sell |
1,817,300
-1,465,600
| -45% | -$209M | 0.07% | 207 |
|
|
2022
Q1 | $566M | Buy |
3,282,900
+217,600
| +7% | +$36.6M | 0.12% | 91 |
|
|
2021
Q4 | $779M | Buy |
3,065,300
+196,000
| +7% | +$57.3M | 0.16% | 59 |
|
|
2021
Q3 | $1.1B | Buy |
2,869,300
+251,900
| +10% | +$92.9M | 0.23% | 42 |
|
|
2021
Q2 | $615M | Sell |
2,617,400
-709,600
| -21% | -$127M | 0.14% | 72 |
|
|
2021
Q1 | $436M | Buy |
3,327,000
+954,900
| +40% | +$138M | 0.11% | 105 |
|
|
2020
Q4 | $248M | Buy |
2,372,100
+731,200
| +45% | +$74M | 0.06% | 191 |
|
|
2020
Q3 | $116M | Buy |
1,640,900
+876,300
| +115% | +$61.1M | 0.03% | 388 |
|
|
2020
Q2 | $49.1M | Buy |
764,600
+534,200
| +232% | +$29.3M | 0.02% | 814 |
|
|
2020
Q1 | $6.9M | Buy |
230,400
+198,800
| +629% | +$4.57M | ﹤0.01% | 2301 |
|
|
2019
Q4 | $618K | Sell |
31,600
-45,400
| -59% | -$805K | ﹤0.01% | 6463 |
|
|
2019
Q3 | $1.23M | Buy |
77,000
+11,000
| +17% | +$162K | ﹤0.01% | 5239 |
|
|
2019
Q2 | $966K | Buy |
66,000
+31,400
| +91% | +$674K | ﹤0.01% | 5755 |
|
|
2019
Q1 | $704K | Buy |
+34,600
| New | +$642K | ﹤0.01% | 6207 |
|
Other funds holding MRNA
TP
Citadel Advisors's MRNA Position: Q2 2026 in Review
Citadel Advisors reduced its Moderna (MRNA) stake by 40% in Q2 2026, selling an estimated $10.1M and leaving 294,496 shares worth $20.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2542.
Citadel Advisors first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $168M in Q2 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Citadel Advisors held 294,496 shares of Moderna worth $20.6M as of Q2 2026.
- Citadel Advisors sold 195,274 Moderna shares in Q2 2026, an estimated $10.1M.
- Moderna made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2542 holding.
- Citadel Advisors first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
- Citadel Advisors's Moderna position peaked at $168M in Q2 2021.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.